Compare Bristol-Myers Squibb Co (BMY) vs Direxion Daily FTSE China Bull 3x Shares (YINN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Bristol-Myers Squibb Co vs Direxion Daily FTSE China Bull 3x Shares — how do they compare? Bristol-Myers Squibb Co trades at $58.71 (market cap $116.30B), while Direxion Daily FTSE China Bull 3x Shares trades at $27.4. The key difference: Bristol-Myers Squibb Co pays a 4.42% dividend while Direxion Daily FTSE China Bull 3x Shares pays none, and Bristol-Myers Squibb Co is trading nearer its 52-week high, Direxion Daily FTSE China Bull 3x Shares nearer its low. Which is the better fit depends on your goals.
| BMY | YINN | |
|---|---|---|
Market Cap | $116.30B | — |
Sector | Health | Leveraged / Inverse |
52-Week High | $62.37 | $56.62 |
52-Week Low | $42.60 | $21.45 |
Enterprise Value | $152.24B | — |
Dividend Yield | 4.42% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Bristol Myers Squibb (BMY) trades at $59.34, up 3.06% today, with a bullish technical signal and consistent earnings beats. The stock shows strong profitability with a 15.01% net margin and 38.84% ROE, though debt levels have risen. Recent FDA acceptance for mezigdomide in multiple myeloma highlights pipeline progress. Analysts are mixed with a $60 consensus target, slightly above current price.
BMY offers value with a P/E of 16.62 and a safe 4.3% dividend yield, but faces patent cliff risks and pricing pressures. Earnings growth and pipeline execution are key catalysts, while high debt and competitive threats require monitoring. The stock presents a balanced opportunity for income-focused investors with moderate risk tolerance.
YINN, the Direxion Daily FTSE China Bull 3x ETF, trades at $25.25, down 0.43% on the day. Technical indicators show a bullish overall signal with strong moving average support, though oscillators are neutral and RSI_6 suggests overbought conditions. Recent sentiment has improved with a Seeking Alpha rating upgrade from bearish to neutral, citing China's relative undervaluation and improved macro backdrop, though concerns remain about the fund's leveraged structure and value trap risks in Chinese equities.
The outlook for YINN is cautiously optimistic, driven by China's tech sector momentum and substantial government AI investment plans. However, significant risks include geopolitical tensions with the U.S., the fund's 3x leverage amplifying volatility, and ongoing regulatory uncertainties. Investors should weigh China's economic stimulus against structural challenges in the market.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Bristol-Myers Squibb Co
Bristol-Myers Squibb discovers, develops, and markets drugs for various therapeutic areas, such as cardiovascular, cancer, and immune disorders. A key focus for Bristol is immuno-oncology, where the firm is a leader in drug development. Unlike some of its more diversified peers, Bristol has exited several nonpharmaceutical businesses to focus on branded specialty drugs, which tend to support strong pricing power.
Read more on BMY →About Direxion Daily FTSE China Bull 3x Shares
YINN is a leveraged ETF that seeks daily investment results, before fees and expenses, of 300% (3x) of the daily performance of the FTSE China 50 Index. It is a tactical instrument designed for sophisticated traders seeking to magnify short-term bullish views on large-cap Chinese equities, primarily those trading on the Hong Kong Stock Exchange.
Read more on YINN →
